University of Hertfordshire

Cyclosporine in severe childhood atopic dermatitis: a multicenter study

Research output: Contribution to journalArticle

  • J Berth-Jones
  • A Y Finlay
  • I Zaki
  • B Tan
  • H Goodyear
  • S Lewis-Jones
  • M J Cork
  • S S Bleehen
  • M S Salek
  • B R Allen
  • S Smith
  • R A Graham-Brown
View graph of relations
Original languageEnglish
Number of pages6
Pages (from-to)1016-21
JournalJournal of the American Academy of Dermatology
Journal publication dateJun 1996
Volume34
Issue6
Publication statusPublished - Jun 1996

Abstract

BACKGROUND: Severe atopic dermatitis (AD) remains difficult to treat. Cyclosporine is effective in adults but has not previously been investigated in children with AD.

OBJECTIVE: The aims were to investigate the efficacy, safety, and tolerability of cyclosporine in severe refractory childhood AD.

METHODS: Subjects 2 to 16 years of age were treated for 6 weeks with cyclosporine, 5 mg/kg per day, in an open study. Disease activity was monitored every 2 weeks by means of sign scores, visual analogue scales for symptoms, and quality-of-life questionnaires. Adverse events were monitored. Efficacy and tolerability were assessed with five-point scales.

RESULTS: Twenty-seven children were treated. Significant improvements were seen in all measures of disease activity. Twenty-two showed marked improvement or total clearing. Quality of life improved for both the children and their families. Tolerability was considered good or very good in 25 subjects.

CONCLUSION: Cyclosporine may offer an effective, safe, and well-tolerated short-term treatment option for children with severe AD.

ID: 14614154